Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M28,187Revenue $M580Net Margin (%)-127.3Z-Score10.9
Enterprise Value $M27,628EPS $-3.1Operating Margin %-119.4F-Score3
P/E(ttm))0Cash Flow Per Share $-0.3Pre-tax Margin (%)-126.7Higher ROA y-yN
Price/Book25.810-y EBITDA Growth Rate %0Quick Ratio4.1Cash flow > EarningsY
Price/Sales47.25-y EBITDA Growth Rate %0Current Ratio4.2Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-32.5Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-61.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M242ROI % (ttm)-31.5Gross Margin Increase y-yY

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXVanguard Health Care Fund 2014-12-31 Reduce-0.58%$101.1 - $120.78
($112.61)
$ 116.433%Reduce -16.93%9,808,860
VRTXAndreas Halvorsen 2014-12-31 Buy 0.42%$101.1 - $120.78
($112.7)
$ 116.433%New holding764,200
VRTXKen Fisher 2014-09-30 Reduce$84.74 - $113.9
($94.97)
$ 116.4318%Reduce -31.99%4,593
VRTXGeorge Soros 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 116.4340%Sold Out0
VRTXJohn Burbank 2014-06-30 Sold Out -0.01%$62.44 - $93.77
($69.73)
$ 116.4340%Sold Out0
VRTXKen Fisher 2014-06-30 Buy $62.44 - $93.77
($69.73)
$ 116.4340%New holding6,753
VRTXVanguard Health Care Fund 2014-03-31 Add0.13%$67.8 - $85.48
($79.08)
$ 116.4332%Add 5.89%11,628,500
VRTXJohn Burbank 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 116.4332%New holding2,872
VRTXGeorge Soros 2014-03-31 Buy 0.01%$67.8 - $85.48
($79.17)
$ 116.4332%New holding10,000
VRTXVanguard Health Care Fund 2013-12-31 Add0.88%$60.18 - $77.83
($69.45)
$ 116.4340%Add 54.06%10,981,500
VRTXVanguard Health Care Fund 2013-09-30 Add0.29%$74.53 - $88.51
($79.62)
$ 116.4332%Add 19.00%7,127,997
VRTXVanguard Health Care Fund 2013-06-30 Add1.05%$52.6 - $85.6
($73.64)
$ 116.4337%Add 140.58%5,990,000
VRTXAndreas Halvorsen 2013-06-30 Sold Out -0.26%$52.6 - $85.6
($73.64)
$ 116.4337%Sold Out0
VRTXNWQ Managers 2013-06-30 Sold Out -0.09%$52.6 - $85.6
($73.64)
$ 116.4337%Sold Out0
VRTXAndreas Halvorsen 2013-03-31 Buy 0.26%$41.9 - $54.97
($47.91)
$ 116.4359%New holding780,500
VRTXNWQ Managers 2013-03-31 Reduce-0.02%$41.9 - $54.97
($47.91)
$ 116.4359%Reduce -23.44%191,032
VRTXDaniel Loeb 2012-12-31 Sold Out -0.77%$38.88 - $59.42
($46.08)
$ 116.4360%Sold Out0
VRTXJohn Burbank 2012-12-31 Sold Out -0.38%$38.88 - $59.42
($46.08)
$ 116.4360%Sold Out0
VRTXDaniel Loeb 2012-09-30 Add0.22%$48.38 - $59.07
($53.5)
$ 116.4354%Add 40.00%700,000
VRTXJohn Burbank 2012-09-30 Reduce-0.09%$48.38 - $59.07
($53.5)
$ 116.4354%Reduce -25.00%150,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Silva Paul MSVP & Corp Controller 2015-03-23Sell2,250$125.65-6.41view
SMITH IAN FEVP & CFO 2015-03-23Sell6,042$125.67-6.42view
Sachdev AmitEVP, Policy, Access & Value 2015-03-23Sell17,083$132.28-11.1view
Riley Wayne JosephDirector 2015-03-20Sell10,000$135.08-12.94view
SACHS BRUCE IDirector 2015-03-20Sell10,000$135.52-13.22view
SACHS BRUCE IDirector 2015-03-18Sell10,000$130.13-9.63view
Sachdev AmitEVP, Policy, Access & Value 2015-03-18Sell12,000$130-9.54view
BOGER JOSHUA SDirector 2015-03-11Sell11,700$122.96-4.36view
BOGER JOSHUA SDirector 2015-03-11Sell11,700$122.96-4.36view
BOGER JOSHUA SDirector 2015-03-04Sell11,700$121.2-2.97view

Press Releases about VRTX :

    Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    J.P. Morgan Chimes In With Ratings On BioTech Stocks Jan 06 2015 
    William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 
    Weekly CFO Sells Highlight: Texas Instruments Inc, Royal Caribbean Cruises Ltd, Vertex Pharmaceutica Nov 09 2014 
    Weekly CFO Sells Highllight: Facebook Inc, Vertex Pharmaceuticals Inc, Nike Inc. Oct 06 2014 
    Vanguard Health Care Fund Buys Vertex Pharmaceuticals, Zoetis Inc, , Sells Cerner Corporation, AbbVi Aug 02 2013 
    Weekly Guru Bargains Highlights: MBI, VRTX, GRPN, PBI, PC Dec 16 2012 
    WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 22 2012 
    Idenix Pharmaceuticals Lagging Behind in Breakthrough Hepatitis C Drug Development Jul 13 2012 
    Weekly Top Insider Sells: GMCR, VRTX, CERN, and AGN May 14 2012 
    Vertex Could Climb On New Drug, VX-222 Success Apr 22 2012 


    More From Other Websites
    Biotech Stock Selloff: Is It Justified? Mar 26 2015
    The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases Mar 26 2015
    Science, patients driving rare disease drug research surge Mar 25 2015
    Why Deutsche Bank Says to Buy Gilead and Vertex Pullbacks Mar 25 2015
    Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - Analyst Blog Mar 24 2015
    Vertex Treatment May Have High Risk of Failure, Analyst Suggests Mar 24 2015
    Stock Market News for March 24, 2015 - Market News Mar 24 2015
    Deutsche Bank: Vertex Pharma's Disappointing VX-661 Trial Results Isn't The End Mar 23 2015
    Vertex Falls Below Buy Point On Cystic-Fibrosis Drug Data Mar 23 2015
    Pfizer and ImmunoGen are big market movers Mar 23 2015
    Major averages dropped into the close... Mar 23 2015
    Why you shouldn’t read too much into the latest Vertex trial results Mar 23 2015
    Apple climbs after $1tn valuation call Mar 23 2015
    ICYMI: Pharmaceutical Stocks Are Moving Big On Monday Mar 23 2015
    Vertex Tumbles As Cystic Fibrosis Data Disappoints Mar 23 2015
    Biotech stocks on pace to snap 8-day win streak as warnings abound Mar 23 2015
    Vertex Pharmaceuticals (VRTX) Stock Falls Today on Cystic Fibrosis Drug Trial Data Mar 23 2015
    Stocks Stage Low-Drama Start; Vertex Weighs On Nasdaq Mar 23 2015
    Cramer's Mad Dash: Red-hot cyber play Mar 23 2015
    Vertex Cystic-Fibrosis Drug Smacked by Burden of High Expectations Mar 23 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK